SWOG A Randomized; Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients Who Have Progressed Systematically After Previous Clinical Benefit From Crizotinib Monotherapy<br> Adult CIRB - Early Phase Emphasis Completed Completed